Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Cell+Rep+Med 2020 ; 1 (3): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients #MMPMID32835303
Suthar MS; Zimmerman MG; Kauffman RC; Mantus G; Linderman SL; Hudson WH; Vanderheiden A; Nyhoff L; Davis CW; Adekunle O; Affer M; Sherman M; Reynolds S; Verkerke HP; Alter DN; Guarner J; Bryksin J; Horwath MC; Arthur CM; Saakadze N; Smith GH; Edupuganti S; Scherer EM; Hellmeister K; Cheng A; Morales JA; Neish AS; Stowell SR; Frank F; Ortlund E; Anderson EJ; Menachery VD; Rouphael N; Mehta AK; Stephens DS; Ahmed R; Roback JD; Wrammert J
Cell Rep Med 2020[Jun]; 1 (3): ä PMID32835303show ga
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there is a pressing need to understand the development, specificity, and neutralizing potency of humoral immune responses during acute infection. We report a cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients. RBD-specific IgG responses are detectable in all patients 6 days after PCR confirmation. Isotype switching to IgG occurs rapidly, primarily to IgG1 and IgG3. Using a clinical SARS-CoV-2 isolate, neutralizing antibody titers are detectable in all patients by 6 days after PCR confirmation and correlate with RBD-specific binding IgG titers. The RBD-specific binding data were further validated in a clinical setting with 231 PCR-confirmed COVID-19 patient samples. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.